Market Overview

ChemoCentryx Says Glaxo's Top-Line Results from SHIELD-1 Phase III Study of Vercirnon Did Not Meet Primary Endpoint

Share:
Related GSK
Five Prime Therapeutics Announces Oral Presentation of Initial Data From Ongoing Phase 1b Trial of FP-1039/GSK3052230 in Squamous Non Small Cell Lung Cancer and Mesothelioma at World Conference on Lung Cancer
US Stock Futures Slide Ahead Of Deere, Foot Locker Earnings
Seeking U.S. And Asian Stocks With Consistently High ROEs At 52-Week Lows (Seeking Alpha)
Related CCXI
Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 3
Biggest Gainers From Friday, December 12, 2014

ChemoCentryx, Inc. (Nasdaq: CCXI) reports that GlaxoSmithKline (NYSE: GSK) announced today that the first of four Phase III studies, the SHIELD-1 study, investigating vercirnon, an inhibitor of the chemokine receptor known as CCR9, in patients with moderate-to-severe Crohn's disease did not achieve the primary endpoint of improvement in clinical response and the key secondary endpoint of clinical remission. The rates of serious adverse events and withdrawals due to adverse events were similar among all treatment groups including the placebo group, with a trend in dose-dependent increases in overall adverse event rates. GSK has indicated that it intends to continue to explore the safety and efficacy results to inform decisions about the clinical development program for vercirnon. New recruitment and dosing in the ongoing clinical program has been suspended pending further review of the SHIELD-1 results.

Posted-In: News FDA

 

Related Articles (GSK + CCXI)

Get Benzinga's Newsletters